Metsera, Inc. (MTSR:NASDAQ) closed at $70.50 on November 13, 2025, down 0.35% on the day. The stock trades 15.9% below its 52-week high of $83.86 and 473.2% above its 52-week low of $12.30. Metsera, Inc. is part of the Health Care sector.
In 252 trading sessions since October 22, 2025, MTSR closed higher on 5 days (2%). Its best day was October 30, 2025 (+22.06%) and its worst was November 10, 2025 (-14.80%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 2 times.
Metsera is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. We use our proprietary MINT peptide library of NuSH analog peptides alongside our Half-life Augmentation by Lipid Optimization, or HALO, half-life extending platform and our MOMENTUM oral NuSH analog peptide delivery platform to deliver highly differentiated product candidates that we are advancing into clinical trials for obesity or overweight. MET-097i, our most advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA that we are developing for the treatment of obesity and overweight. We have an ongoing Phase 1/2 clinical trial of MET-097i in the United States in participants who are obese or overweight but otherwise healthy.
Find more stocks like MTSR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.